Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway
Authors
Keywords
-
Journal
CARCINOGENESIS
Volume 33, Issue 12, Pages 2391-2397
Publisher
Oxford University Press (OUP)
Online
2012-09-16
DOI
10.1093/carcin/bgs288
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
- (2011) Andrew X. Zhu et al. CANCER
- DCAMKL-1 Regulates Epithelial-Mesenchymal Transition in Human Pancreatic Cells through a miR-200a-Dependent Mechanism
- (2011) S. M. Sureban et al. CANCER RESEARCH
- mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways
- (2011) P. Gulhati et al. CANCER RESEARCH
- MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab
- (2011) N. Nishida et al. CLINICAL CANCER RESEARCH
- Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer
- (2011) Murugan Kalimutho et al. JOURNAL OF GASTROENTEROLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets
- (2010) Wenzhang Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Rapamycin Regulates Endothelial Cell Migration through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1
- (2010) Stephanie C. Moss et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- The miR-144/451 locus is required for erythroid homeostasis
- (2010) Kasper D. Rasmussen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- A dicer-independent miRNA biogenesis pathway that requires Ago catalysis
- (2010) Sihem Cheloufi et al. NATURE
- mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer
- (2009) Yan-Jie Zhang et al. ANNALS OF SURGICAL ONCOLOGY
- Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
- (2009) P. Gulhati et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started